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determination. 22 drugs met NICE’s EOL-SPP for the indication for which they were
being appraised. Twelve of these drugs had the EOL-SPP criterion applied to the
only indication for which they were licensed. The EOL-SPP criterion was applied to
the cumulative populations of ten drugs which had marketing authorization for
more than one indication. The seven drugs that did not meet the EOL-SPP criterion
all had individual indications which were within the number of what is considered
acceptable (7,000), but had total cumulative populations that were greater. Two
STAs in particular stand out. The appraisal committee accepted that panitumumab
met the EOL-SPP criterion for its current indication but noted that the EMA recom-
mended a marketing extension which would raise the expected patient population
to 10,000. In its final appraisal determination for abiraterone NICE overturned its
original decision that the drug did not meet the EOL-SPP criterion, even though it
noted that abiraterone may be recommended for a marketing extension for a
greater patient population. CONCLUSIONS: There is no evidence to suggest NICE
applies the EOL-SPP to the cumulative populations of currently licensed indications
plus potential future indications.
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OBJECTIVES: To compare the contrasting approaches in France and the UK for
assessing the value added by new drugs METHODS: We reviewed the technology
appraisals performed by the National Institute for Health and Clinical Excellence
(NICE) on 38 anticancer drugs in the UK from September 2003 to January 2012.
Estimates of the quality-adjusted life-years (QALYs) gained and incremental cost
per QALY gained were then compared the assessments of the Amélioration du
Service Médical Rendu (ASMR) made by the Haute Autorité de Santé (HAS) in France
for the same drugs in the same clinical indications. RESULTS: In the UK, the esti-
mates of QALYs gained ranged from 0.018 to 1.85 and estimates of incremental
cost-per QALY from £1800 to £458,000. The estimate of incremental cost per QALY
was a good predictor of the level of restriction imposed on the use of the drug
concerned. Patient access schemes, which normally imply price reductions, were
proposed in 45% of cases. In France, the distribution of ASMRs was 1, 16%; 2, 8%; 3,
21%; 4, 24%; 5, 24%; and uncategorized/ non-reimbursed, 8%. Since ASMRs of 4 and
above signify minor or no improvement over existing therapy, these ratings imply
that, in around half the cases, the drugs concerned would face price controls.
Overall, the assessments of value added in the two jurisdictions produced very
similar results. A superior ASMR rating was a good predictor of both higher QALYs
gained and a lower incremental cost per QALY. CONCLUSIONS: We conclude that,
despite the contrasting approaches employed in France and the UK for assessing
the value added by new drugs, the overall assessments of value added produced
very similar results. However, the implications of these assessments for patient
access to, and prices of, anticancer drugs in the two jurisdictions require further
investigation.
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OBJECTIVES: To examine the similarities and differences in the HTAs conducted in
6 countries in the last 5.5 years in the areas of cardiology and oncology, the thera-
peutic areas of greatest mortality. METHODS: We reviewed and abstracted infor-
mation from 768 cardiology and 960 oncology HTAs conducted from January 1, 2007
to June 23, 2012. Our primary focus was those made by the following public orga-
nizations: Canadian Agency for Drugs and Technology in Health, Haute Autorite de
Sante, Institute for Quality and Efficiency in Health Care, National Institute for
Clinical Excellence, Pharmaceutical Benefits Advisory Committee, Medical Services
Advisory Committee, and the Agency for Healthcare Research and Quality. For
comparative purposes and overall interest, we also studied the HTAs of the follow-
ing private American organizations: BlueCross BlueShield Technology Evaluation
Center, California Technology Assessment Forum, Drug Effectiveness Review Pro-
gram, Healthcore/Wellpoint, Institute for Clinical and Economic Review, and the
MedCo Research Institute, and the multinational Cochrane Collaboration. Finally,
we looked at the American Recovery and Reinvestment Act generated CER grants
recently made by the federal government to the National Institutes of Health and
the Department of Health and Human Services to determine any new directions in
the US. Cardiology HTAs were divided into 12 sub-therapeutic categories; oncology
18 for ease of analysis. Variables analyzed included specific subject of HTA and
analytic methods, date of release, and results. RESULTS:Market entry of drugs and
selected devices tended to affect HTA content and timing; country processes for
review also affect these variables and results. HTAs of other single interventions
and multiple modality comparisons were more variable as to timing, content, and
results.CONCLUSIONS: Both the commonalities and differences found in the HTAs
lend themselves to the examination of potential economies of evidence assess-
ment and bases for optimal patient care. The authors provide suggestions for policy
makers.
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OBJECTIVES: The German AMNOG health care reform includes a mandatory EBA of
innovative medicines at launch. As per German social code, EBA is based on regis-
tration trials and must include evaluation of the patient-relevant, therapeutic ef-
fect of the new medicines compared to an appropriate comparator as defined by
the Federal Joint Committee (G-BA). Current EBA decisions released have unveiled
issues regarding the acceptance of some PRE as G-BA and IQWiG are grading the
endpoints, focusing on overall survival (OS) as the preferred endpoint in oncology.
METHODS:A task force under the auspices of the German Association of Research-
based Pharmaceutical Companies (vfa) was appointed. Members were experienced
German outcomes research, medical, HTA and biostatistics researchers in indus-
try. After agreement on core assumptions developed and outlined by the Task
Force, a draft position was prepared. Input on iterative versions was solicited from
a panel of reviewers from industry and external stakeholders. RESULTS: Distinc-
tive features of registration trials in oncology need to be considered when these
studies form basis for EBA, especially in cancer indications with long post-progres-
sion survival time; and with several consecutive therapeutic options available fol-
lowing progression. Besides, ethical committees, caregivers and patients often de-
mand cross-over-designs diluting over the treatment effect on OS. Also, regulatory
authorities require evaluation of morbidity-related study endpoints including sur-
vival of patients without their disease getting worse (i.e., progression-free survival).
Fear of progression is a key feature in oncological conditions. Furthermore progres-
sion usually requires treatment changes, another strong indicator for its relevance
to patients. CONCLUSIONS: PRE in oncology depend on tumor- and tumor-stage-
specific factors. For decades, endpoints have been thoroughly evaluated, resulting
in specific guidelines and clinical trial programs that were developed in-line with
regulatory guidance. This extensive knowledge and experience should be fully
acknowledged during EBA when assessing the patient-relevant benefit of innova-
tive medicines in oncology.
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OBJECTIVES: A Breast Cancer Outcomes & Policy (BCOP) microsimulation model is
being developed to evaluate the 21-gene recurrence score assay that guides adju-
vant chemotherapy in Austria. The goal is to adapt the model to a United States
(US) context using real-world data from the Huntsman-Cancer-Institute (HCI) in
Utah. We aim to study the impact of real-world data and country-specific settings
on cost-effectiveness results. METHODS: The BCOP-model simulates a hypotheti-
cal cohort of 50year old women over a lifetime time horizon using a discrete-event-
simulation. To inform this model, a cohort of early breast cancer patients was
identified at the HCI based on ICD-9 codes(174.0-174.9) and inclusion in the HCI
registry for invasive breast cancer from 2005-2010. Patients were included with
stage I to IIIa disease at diagnosis, documented curative intent surgery, use of
endocrine therapy, and lack of HER2 directed therapies. Patients receiving adjuvant
chemotherapy were identified. Price for chemotherapy was based on average
wholesale price (AWP). RESULTS: A total of 367 patients with early stage breast
cancer were identified with a mean age of 58.2 years. There were 123 patients
(33.5%) treated with adjuvant chemotherapy. Among the 123 patients treated with
chemotherapy, 21%, 64.2% and 14.6% were stage I, II and IIIa respectively; which
comprised 12.3%, 57.7%, and 64.3% of all stage I, II, and IIIa patients, respectively.
The predominate chemotherapy regimen was doxorubicin and cyclophosphamide
with or without paclitaxel for 72% of patients. The AWP for this regimen is $4476
with and $1507 without paclitaxel, respectively; the AWP of Oncotype Dx is $4175.
One of the challenges faced during model development was that many of the
variables needed require chart reviews. CONCLUSIONS: Extraction of data from a
real-world breast cancer cohort provided reference data on treatments and costs to
inform the BCOP- model.
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OBJECTIVES: Population-based registries provide insights into quality of care and
inform reimbursement decisions. This study aims to investigate whether registries
are a suitable tool for outcomes research in assessing drug use and real-world
cost-effectiveness in cancer. METHODS: We used four Dutch population-based
registries to conduct outcomes research. Patients for the registries were included
regardless of prognosis or treatment: 55% and 40% of all Dutch patients in meta-
static renal cell cancer (mRCC) and three haematological cancers, respectively.
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Data were retrospectively collected at several points in time from medical records
and hospital information systems on baseline characteristics, treatments, dosages,
treatment response, survival, adverse events and resource use. All patients entered
the registry at time of diagnosis. RESULTS: Our registries contained information of
615 mRCC and 3093 haematological cancer patients (non-Hodgkin, multiple my-
eloma, and chronic lymphocytic leukaemia). They provided important information
about how patients, including those regularly excluded from clinical trials, are
treated in daily practice. However, important data, including prognostic informa-
tion, was commonly missing (e.g. 40-55% missing performance status). Further-
more, patients treated with the drug of interest were not comparable to patients
not treated with this drug. Moreover, only small numbers of patients received the
drug of interest (mRCC: N34; non-Hodgkin: N35), and many patients received
different drugs in various combinations and treatment sequences in haematologi-
cal cancers. This, in combination with the inability to fully correct for confounding,
complicates the estimation of a real-world incremental cost-effectiveness
estimate. CONCLUSIONS: Our registries provided important information to physi-
cians and policymakers to enhance quality of care and facilitate evidence-based
decision making. Although population-based registries include high numbers of
patients, it remains a challenge to obtain sufficient numbers of similarly treated
and comparable patients. Therefore, it is inevitable to use data synthesis in com-
bination with comprehensive modelling techniques to obtain valid real-world in-
cremental cost-effectiveness estimates.
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OBJECTIVES: Smoking is a leading cause of early dead and morbidity in the West-
ern World. The purpose of this study is to evaluate how tobacco sales and tobacco
survey data correlates with lung cancer incidence in the Danish population. It is
estimated that up to 86% of lung cancer cases in developed countries are smoking
related. METHODS: Lung cancer incidence data from 1943-2009 are from Nordcan
(www.ancr.nu). Sale of tobacco (cigarettes/inhabitant) 1920-2010. Smoking habit
surveys from 1953-2010, annually from 1969. Lung cancer incidence is age stan-
dardized to the Nordic population (ASR(N)), and is in rate per 100.000/year. Corre-
lations are analyzed with Spearman’s rho with SPSS18. RESULTS: The strongest
correlation (spearman’s rho  0.92, p0.0001) is found between sale of cigarettes
and incidence of lung cancer with a lag time of 24 years. The correlation between
lung cancer and the proportion of the population that smokes is well correlated for
men (0.8, p0.0001, lag time20 years). Female smokers and lung cancer are with
a lag time of 5-26 years negatively correlated, but correlates positively when the lag
time is more than 27 years, the best correlation being 0.732 (p0.039, lag time35
years).CONCLUSIONS: The correlation between lung cancer incidence and the sale
of cigarettes is better than for the proportion of smokers. This might be because
sale gives a better estimation of the overall exposure in a form of population “pack
years”. The negative correlation between the proportion of female smokers and
lung cancer, and the change to a positive correlation when a longer lag time is
applied can be either a true finding that might be explained by longer development
time in females. Or it could be a result of changes in the accuracy of the proportion,
or a result of changes in the age pattern.
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OBJECTIVES: The new value-based system of pricing branded medicines in the UK
is nearing the launch phase with unresolved concerns towards developing the new
pricing framework and executing the system. This study identifies the strategies
proposed by stakeholders for the successful implementation of VBP and also de-
termines the ‘relative importance weights’ of additional value-elements i.e., bur-
den of illness, innovation and societal benefit introduced in the new pricing
framework. METHODS: In-depth qualitative and survey-based interviews were
conducted with 23 experts identified in pharmaceutical industry, NHS and SMC
advisory committees, NHS hospitals and pharmacies. RESULTS: Pharmaceutical
industry should adapt to a new model that brings innovation in R&D, addresses
unmet need and demonstrates the value of a new drug by gathering real-world
evidence. Government or payers should proactively publish guidelines before the
launch or propose a transitional arrangement for pharma in 2014. The local uptake
of medicines should be encouraged by introducing national settlement schemes
and incentivizing the local commissioning groups. It is possible that government
and pharmaceutical industry will direct more efforts towards improving the inter-
action between prescribers and patients for gathering real-world evidence. The
results also indicated that clinical-effectiveness and cost-effectiveness will remain
the prime metric in valuation process, however, burden of illness and innovation
may carry more weight than other value-elements. Societal benefit still needs to be
broadly defined; and innovation should ultimately translate into improved clinical
efficacy. The study also highlights the impact of VBP on each stakeholder group and
across disease areas with a focus on primary care and oncology. CONCLUSIONS:
The stakeholders still lack the clear understanding of VBP and believe that ulti-
mately it might be restructuring of the existing system given the limited time left
for its implementation. Even though the new pricing framework includes addi-
tional criteria, pricing decisions are anticipated to be made on a case-by-case basis
eventually.
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OBJECTIVES: Patient access or risk sharing schemes (PASs) have recently been
increasingly used, enabling easier and swifter access to new treatments, especially
in oncology. However, PASs frequently do not deliver the required results. The aim
was to create a conceptual framework that allows the selection of the most appro-
priate PAS in different countries. METHODS: A targeted literature review has been
conducted to identify PAS specific literature in oncology. Based on the review and
the evaluation of the currently implemented PASs in the EU, a three-level concep-
tual framework has been constructed. It is based on a list of criteria identified as
country-specific prerequisite for the different types of PASs. Each criterion can be
achieved by different tools/techniques, each with a list of basic requirements. PASs
for each country can be evaluated using simple scoring system for each criterion.
The proposed framework has been validated by EU industry experts and payer’s
representatives and tested for the UK and Hungary.RESULTS:The literature review
identified large number of abstracts and studies; however only 14 met the inclusion
criteria. These were mainly from the UK and US. The criteria evaluated authorities’
roles and responsibilities, transparency throughout the negotiation process and
implementation phase for all stakeholders, presence of trust and cooperation
among payers and manufacturers, availability of budget, clear patient pathways,
data availability, administration capacity and appropriate incentives for the stake-
holders. The test results were in accordance with the expert’s views and empha-
sized the insights from recent experiences and case studies. CONCLUSIONS: The
conceptual framework offers a good starting point for the evaluation of the poten-
tial success of the different PASs in oncology in a given country. Future steps could
include extension of therapeutic area, incorporation of relative weights for the
criteria and extending the countries used for validation.
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OBJECTIVES: We evaluated the use of confirmatory HER2 fluorescence in situ hy-
bridisation (FISH) and predictors of trastuzumab use in early-stage breast cancer
(ESBC) in the province of Ontario. The adherence of practice patterns to provincial
adjuvant trastuzumab treatment guidelines and national HER2 testing consensus
guidelines was assessed. METHODS: A retrospective cohort of ESBC patients diag-
nosed in 2006-7 was identified in the Ontario Cancer Registry (OCR). HER2 test type,
sequence, result(s) and status, tumour grade and hormone receptor status were
determined from centrally-held (OCR) pathology reports. Trastuzumab treatment
was determined from provincial cancer agency records. Demographic, local health
integration network (LHIN), surgical, prior radiological and anthracycline treat-
ment and comorbidity data were determined from administrative data sources.
Logistic models were used to estimate adjusted odds ratios for factors associated
with guideline adherence. RESULTS: The first HER2 test result was the largest
predictor of confirmatory testing, with HER2 equivocal tumours being significantly
more likely to be retested vs. positive (OR 116 [79, 169]). Confirmatory testing varied
by LHIN but not by age. Patients diagnosed with stage III disease had significantly
higher odds of receiving a confirmatory test vs. stage I (OR 1.5 [1.1, 2.1]). HER2 status
was the largest predictor of trastuzumab use in the cohort, with HER2 equivocal,
negative or unknown status patients significantly less likely to receive treatment
than positive. Patients with advanced age at diagnosis (70y) had lower odds of
trastuzumab treatment compared to younger patients (OR 0.5 [0.3, 0.7]). Increasing
tumour grade was associated with higher odds of treatment. Treatment varied
significantly by LHIN. CONCLUSIONS: Despite limitations in centrally-reported tu-
mour pathology, we demonstrate that the use of confirmatory FISH testing in On-
tario was largely consistent with Canadian guidelines. Trastuzumab use in the
cohort was consistent with provincial guidelines on HER2 status in many patients,
though practice varies across LHINs.
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OBJECTIVES: To determine treatment patterns among individuals treated for un-
resectable stage III and IV melanoma in the Brazilian public and private health care
system. METHODS: A retrospective chart review was conducted in patients with
unresectable stage III and IV melanoma or relapsed between January 01 2008 and
December 31 2009. Patients had to have at least two months follow up in 12 private
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